Compare PPC & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PPC | CRSP |
|---|---|---|
| Founded | 1946 | 2013 |
| Country | United States | Switzerland |
| Employees | 52100 | N/A |
| Industry | Meat/Poultry/Fish | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 5.8B |
| IPO Year | 1997 | 2016 |
| Metric | PPC | CRSP |
|---|---|---|
| Price | $29.83 | $56.52 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 17 |
| Target Price | $41.33 | ★ $70.29 |
| AVG Volume (30 Days) | 1.2M | ★ 1.4M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 6.74% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $18,497,553,000.00 | $289,590,000.00 |
| Revenue This Year | $2.46 | $807.72 |
| Revenue Next Year | $1.83 | $172.52 |
| P/E Ratio | $61.58 | ★ N/A |
| Revenue Growth | 3.46 | ★ 9169.85 |
| 52 Week Low | $25.90 | $44.12 |
| 52 Week High | $44.84 | $78.48 |
| Indicator | PPC | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 49.34 | 54.20 |
| Support Level | $29.58 | $50.45 |
| Resistance Level | $29.90 | $60.50 |
| Average True Range (ATR) | 0.85 | 2.30 |
| MACD | -0.20 | -0.16 |
| Stochastic Oscillator | 25.93 | 61.19 |
Pilgrim's Pride is the second-largest poultry producer in the US (59% of 2024 sales), the UK (29% including other European sales), and Mexico (12%). Its UK and European arm also includes pork operations from the 2019 acquisition of Tulip. Pilgrim's sells to chain restaurants, food processors, food distributors, and retail chains. Most of its US and Mexican sales come from fresh chicken, while prepared chicken and pork constitute most of its UK and European sales. JBS owns more than 80% of Pilgrim's Pride's outstanding shares, though it failed to acquire the remaining stake in 2021 after a special board committee deemed JBS's offer undervalued Pilgrim's Pride.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.